Results From Phase I M16-106 Study of Venetoclax Plus Navitoclax in Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

December 7-10, 2019; Orlando, Florida
Venetoclax plus navitoclax (combined with chemotherapy) was well tolerated with promising efficacy in heavily pretreated patients with R/R ALL and LL.
Format: Microsoft PowerPoint (.ppt)
File Size: 192 KB
Released: December 9, 2019


Provided by the Annenberg Center for Health Sciences at Eisenhower in partnership with Clinical Care Options.

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Celgene Corporation
Dova Pharmaceuticals, Inc.
Karyopharm Therapeutics
Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company
Pharmacyclics LLC, an AbbVie Company
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Related Content

From Clinical Care Options (CCO), download a PDF featuring expert answers to clinician questions on CAR T-cell therapy

person default Caron A. Jacobson, MD Jae H. Park, MD Noopur Raje, MD Released: July 19, 2021

Drs George Follows, Paolo Ghia, Veronique Leblond discuss the latest clinical data on BTK inhibitors for the treatment of CLL from Clinical Care Options (CCO)

George Follows, BM, BCh, PhD Paolo Ghia, MD, PhD Veronique Leblond, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: July 19, 2021 Expired: July 18, 2022

Downloadable slideset with highlights from key blood cancers and nonmalignant blood disorders as presented at EHA Virtual Congress 2021, from Clinical Care Options (CCO)

Prof. Charles Craddock, CBE, FRCP (UK) María-Victoria Mateos, MD, PhD Lydia Scarfò, MD Ali T. Taher, MD, PhD Released: July 16, 2021

Commentary on most important safety and adherence issues to counsel patients starting BTK inhibitors, from Clinical Care Options (CCO)

Beth Faiman, PhD, MSN, APRN-BC, AOCN Released: July 15, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.